Our systems are now restored following recent technical disruption, and we’re working hard to catch up on publishing. We apologise for the inconvenience caused. Find out more

Recommended product

Popular links

Popular links


Personalized Drug Screening for Functional Tumor Profiling

Personalized Drug Screening for Functional Tumor Profiling

Personalized Drug Screening for Functional Tumor Profiling

Victoria El-Khoury, Luxembourg Institute of Health
Tatiana Michel, Luxembourg Institute of Health
Hichul Kim, Luxembourg Institute of Health
Yong-Jun Kwon, Luxembourg Institute of Health
June 2022
This ISBN is for an eBook version which is distributed on our behalf by a third party.
Adobe eBook Reader
9781009037235
$23.00
USD
Adobe eBook Reader
USD
Paperback

    Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology.

    Product details

    June 2022
    Adobe eBook Reader
    9781009037235
    0 pages
    This ISBN is for an eBook version which is distributed on our behalf by a third party.

    Table of Contents

    • 1. Rationale for functional profiling in oncology
    • 2. Tumor models in drug screening
    • 3. Cell-based screening platforms for personalized medicine
    • 4. Drug repurposing in personalized oncomedicine
    • 5. Clinical applications of drug screening in oncology
    • 6. Conclusions and perspectives
    • References.
      Authors
    • Victoria El-Khoury , Luxembourg Institute of Health
    • Tatiana Michel , Luxembourg Institute of Health
    • Hichul Kim , Luxembourg Institute of Health
    • Yong-Jun Kwon , Luxembourg Institute of Health